4.6 Article

Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma

期刊

FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.619013

关键词

RhoV; lung adenocarcinoma; gefitinib; AKT; ERK

类别

资金

  1. Recruitment Program of Overseas High-Level Young Talents, Innovative and Entrepreneurial Team [(2018) 2015]
  2. Science and Technology Grant of Jiangsu Province [BE2019758]
  3. Six Talent Peaks Project of Jiangsu Province [TD-SWYY-007]
  4. Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University
  5. Medical Interdisciplinary Research Funding of Henan University [CJ1205A0240011]
  6. Postgraduate Research & Practice Innovation Program of Jiangsu Province [SJKY19_ 1327]
  7. China Scholarship Council [201908320572]
  8. Nanjing Medical University Scholarship [C124]
  9. High-Level Talents Program of Nanjing Medical University

向作者/读者索取更多资源

The study revealed that overexpression of RhoV in lung adenocarcinoma promotes tumor progression and resistance to EGFR-TKI, potentially worsening patient prognosis. This suggests that RhoV could be a promising therapeutic target for lung adenocarcinoma.
Background The Rho GTPase family with similar to 20 member genes play central roles in a wide variety of cellular processes and tumor cell migration and metastasis. Different Rho GTPase may play different roles in the progression of lung adenocarcinoma. Methods We comprehensively examined the expression of all Rho GTPase family member genes in a panel of lung adenocarcinoma patient's tumors and matched normal tissues. We next investigated the critical role of RhoV in different lung adenocarcinoma cells and animal models. Results RhoV was identified as one of the most significantly overexpressed Rho GTPases in lung adenocarcinoma and associated with patients' survival. Silencing RhoV expression inhibits proliferation, migration and invasion, and tumorigenicity capacities of lung adenocarcinoma cells. Moreover, knockdown RhoV promoted the sensitivity of EGFR-TKI in the gefitinib resistant PC9 cells (PC9-GR) and aggravated gefitinib-induced lung cancer cell apoptosis both in PC9 and PC9-GR cells. Our data also indicated that RhoV induced progression and EGFR-TKI resistance of lung adenocarcinoma may be related to the activation of the AKT/ERK pathway. Conclusion Overexpression of RhoV in lung adenocarcinoma promotes the progression and EGFR-TKI resistance, suggesting RhoV is a promising prognosis and therapeutic target of lung adenocarcinoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据